{"title":"Evans Syndrome: Analysis of 1255 Adult Cases in US Hospitals, Revealing Demographics, Associations, and Outcomes.","authors":"Rushin Patel, Mrunal Patel, Fehmida Laxmidhar, Darshil Patel, Zalak Patel, Safia Shaikh, Khushboo Lakhatariya","doi":"10.18502/ijhoscr.v19i2.18546","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Evans syndrome (ES) is a rare immune disorder characterized by immune thrombocytopenia and warm autoimmune hemolytic anemia (wAIHA), with the possibility of autoimmune neutropenia (AIN). Limited data due to its rarity led us to perform a descriptive analysis of demographics, outcomes, and comorbidities. <b>Materials and Methods:</b> This study used the National Inpatient Sample database to identify Evans syndrome hospitalizations (ICD-10 code D69.41) from 2016 to 2019, with national estimates. We collected demographic data, examined outcomes, and assessed patient comorbidity. STATA Version 17 was used for data analysis. <b>Results:</b> In our study of 1,255 ES hospitalizations, the mean age was 50.13 years, with a relatively even gender distribution. The racial breakdown included White (59.6%), Black (17.1%), and Hispanic (14.6%). Most had Medicare (41.8%), Medicaid (20.4%), or private insurance (33.5%). Charlson Comorbidity Index scores varied, with 36.6% scoring 3 or more. Non-elective admissions accounted for 90.2% of cases, coming from various U.S. Census Divisions, with East North Central (16.2%) and Pacific (16.1%) leading. Large urban teaching hospitals handled 84.1% of cases. Mortality was 5.5%, the mean stay was 7.8 days, with total charges averaging $114,696. Notable associations included SLE (15.63%), ITP (37%), and anemia (53.5%). Inpatient risks included AKI (22.47%) and sepsis (15.33%). Interventions included red blood cell transfusion (18.65%) and platelet transfusion (10.44%). <b>Conclusion:</b> This study offers key insights into ES in hospitalized adults, emphasizing demographic trends and important associations with other conditions. More research is required to enhance our understanding of ES and enhance outcomes for those affected.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 2","pages":"93-100"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368710/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hematology-oncology and stem cell research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijhoscr.v19i2.18546","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Evans syndrome (ES) is a rare immune disorder characterized by immune thrombocytopenia and warm autoimmune hemolytic anemia (wAIHA), with the possibility of autoimmune neutropenia (AIN). Limited data due to its rarity led us to perform a descriptive analysis of demographics, outcomes, and comorbidities. Materials and Methods: This study used the National Inpatient Sample database to identify Evans syndrome hospitalizations (ICD-10 code D69.41) from 2016 to 2019, with national estimates. We collected demographic data, examined outcomes, and assessed patient comorbidity. STATA Version 17 was used for data analysis. Results: In our study of 1,255 ES hospitalizations, the mean age was 50.13 years, with a relatively even gender distribution. The racial breakdown included White (59.6%), Black (17.1%), and Hispanic (14.6%). Most had Medicare (41.8%), Medicaid (20.4%), or private insurance (33.5%). Charlson Comorbidity Index scores varied, with 36.6% scoring 3 or more. Non-elective admissions accounted for 90.2% of cases, coming from various U.S. Census Divisions, with East North Central (16.2%) and Pacific (16.1%) leading. Large urban teaching hospitals handled 84.1% of cases. Mortality was 5.5%, the mean stay was 7.8 days, with total charges averaging $114,696. Notable associations included SLE (15.63%), ITP (37%), and anemia (53.5%). Inpatient risks included AKI (22.47%) and sepsis (15.33%). Interventions included red blood cell transfusion (18.65%) and platelet transfusion (10.44%). Conclusion: This study offers key insights into ES in hospitalized adults, emphasizing demographic trends and important associations with other conditions. More research is required to enhance our understanding of ES and enhance outcomes for those affected.
背景:Evans综合征(ES)是一种罕见的免疫性疾病,以免疫性血小板减少症和温热性自身免疫性溶血性贫血(wAIHA)为特征,可能伴有自身免疫性中性粒细胞减少症(AIN)。由于其罕见性,有限的数据导致我们对人口统计学、结果和合并症进行描述性分析。材料和方法:本研究使用国家住院患者样本数据库确定2016年至2019年埃文斯综合征住院情况(ICD-10代码D69.41),并进行国家估计。我们收集了人口统计数据,检查了结果,并评估了患者的合并症。使用STATA Version 17进行数据分析。结果:1255例ES住院患者的平均年龄为50.13岁,性别分布相对均匀。种族分类包括白人(59.6%)、黑人(17.1%)和西班牙裔(14.6%)。大多数人有医疗保险(41.8%)、医疗补助(20.4%)或私人保险(33.5%)。查理森共病指数得分各不相同,36.6%的人得分在3分以上。非选修课入学占90.2%的病例,来自美国各个人口普查部门,以东北中部(16.2%)和太平洋(16.1%)领先。大型城市教学医院处理病例占84.1%。死亡率5.5%,平均住院时间7.8天,总费用平均为114,696美元。值得注意的相关性包括SLE(15.63%)、ITP(37%)和贫血(53.5%)。住院风险包括AKI(22.47%)和败血症(15.33%)。干预措施包括红细胞输注(18.65%)和血小板输注(10.44%)。结论:这项研究为住院成人ES提供了重要的见解,强调了人口统计学趋势以及与其他疾病的重要关联。需要更多的研究来加强我们对ES的理解,并改善受影响者的治疗结果。